Compare Repligen Corporation Common Stock (RGEN) vs Vivmark Residential Common Shares of Beneficial Interest (VMRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Vivmark Residential Common Shares of Beneficial Interest — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Vivmark Residential Common Shares of Beneficial Interest trades at $61.44 (market cap $47.36B). The key difference: Vivmark Residential Common Shares of Beneficial Interest is far larger — about 4.3× Repligen Corporation Common Stock's market cap, and Vivmark Residential Common Shares of Beneficial Interest pays a 4.59% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Vivmark Residential Common Shares of Beneficial Interest for 6 Days on average.
| RGEN | VMRK | |
|---|---|---|
Market Cap | $11.14B | $47.36B |
Volume | 1,259,263 | 4,011,655 |
Sector | Health | Real Estate |
52-Week High | $194.57 | $70.15 |
52-Week Low | $102.87 | $57.98 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.02B | $56.46B |
Dividend Yield | — | 4.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
VMRK trades at $61.2, down 0.08% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $3.04B and net income of $1.05B for 2025, but recent quarterly EPS misses and a slight decline in 2026 profit margins highlight near-term challenges. Recent news includes institutional buying and a credit rating upgrade to 'A' by S&P Global Ratings on August 18, 2026.
The outlook is mixed: analyst consensus is a buy with a $71.67 price target, but technical weakness and earnings misses pose risks. Opportunities include strong profitability and institutional support, while risks involve execution post-merger and market volatility. The stock's valuation metrics suggest it is fairly priced relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Vivmark Residential Common Shares of Beneficial Interest
Vivmark Residential is a residential real estate investment trust that owns and operates apartment communities in U.S. markets. Its portfolio includes apartment homes and development projects.
Read more on VMRK →
